Iovance Biotherapeutics is trading at $13.94, up 4.73% at 9:59 a.m. ET on October 9, 2026; no clear company-specific catalyst was identified for the rise.
- The supplied biotech sector context was down 2.04%, so it does not explain the gain.
- The company’s latest identified press release was an October 1 chief medical officer appointment.
- A reported analyst target increase and September revenue-guidance raise predate this session and do not establish today’s cause.